Close mobile menu×
Close mobile menu

Pamela U. Freda, MD

Board Certifications: 
Endocrinology, Diabetes and Metabolism
Expertise in: 
Neuroendocrinology, Cancer Care
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-2254

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Endocrinology, Diabetes and Metabolism

Clinical Expertise

  • Neuroendocrinology
  • Cancer Care
  • Pituitary Disease
  • Pituitary Tumors
  • Pituitary Neoplasm

Education & Training

  • Columbia University College of Physicians and Surgeons
  • Internship: Columbia Presbyterian Medical Center, NY
  • Residency: Columbia Presbyterian Medical Center, NY
  • Fellowship: Columbia Presbyterian Medical Center, NY

Honors & Awards

1999-2002 Irving Scholar Award

About Pamela Freda

Dr. Pamela Freda is Associate Professor of Medicine at NewYork-Presbyterian Hospital, College of Physicians and Surgeons, Columbia University. Dr. Freda received her undergraduate training at Harvard College and her medical training at the College of Physicians and Surgeons. She completed three years of house staff training on the Medical Service at Columbia Presbyterian Medical Center and her Fellowship in Endocrinology at Columbia, College of Physicians and Surgeons.

Dr. Freda has been the Clinical Director of the Neuroendocrine Unit of Columbia University since 2000. Dr. Freda belongs to a number of professional societies including the Endocrine Society, the Growth Hormone Research Society (GRS) and the Pituitary Society, of which she has served on the Board of Directors since 2010.

She served on the Editorial Board of the Journal of Clinical Endocrinology and Metabolism (2000-2004). Since 2010 she has been an Endocrine Society Self-Assessment Committee Member and since 2003 has been a Quality Reviewer of the Pituitary sections of 'Up to Date Endocrinology'. She served as Chair of the Endocrine Society Task force for the Clinical Guidelines on Pituitary Incidentalomas, which were recently published in Journal of Clinical Endocrinology and Metabolism.

Academic Titles

  • Associate Professor of Medicine at NewYork-Presbyterian/Columbia University Medical Center

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
180 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-2254
Fax:
(212) 305-4815
Primary

Research

Dr. Freda's major research interests are clinical and translational investigations in patients with pituitary tumors. One series of studies focuses on patients with acromegaly, a rare disease characterized by excess GH and IGF-I and their multi-system adverse effects. For these studies she has established a very large cohort of newly diagnosed and postoperative patients with acromegaly. One series of studies examines a novel GH-IGF-I excess specific dysregulation of adipose tissue (AT) and lipodystrophy, which is hypothesized to contribute to insulin resistance, adipokine and appetite hormone dysregulation, endothelial cell dysfunction and ultimately increased CV risk in active acromegaly. The study examines muscle lipid by MRI and 1HMRS, hepatic lipid by 1HMRS, subcutaneous adipose tissue for macrophage infiltration and inflammation and the function of biopsied endothelial cells.

A second large study is a multi-disciplinary collaborative prospective study of clinically non-functioning pituitary adenomas (CNFA). This project prospectively studies two groups of such patients. A group of patients with asymptomatic pituitary lesions that do not require surgical intervention are followed in order to determine the appropriate initial evaluation and follow up as well as the safety of their conservative, non-surgical management. The outcome of patients with symptomatic CNFAs treated with surgery is also studied. The study examines the safety of conservative follow up for patients with small tumor remnants after surgery and determines in which of these patients radiotherapy is needed by examining the risks vs. benefits of post-operatively radiotherapy for residual/recurrent tumors. This project also studies for the first time, prospectively, the impact of the disease and our therapies on quality of life and neurocognitive function in patients with CNFAs and is establishing a novel bank of pituitary tumor specimens from our cohort that will be linked to the extensive clinical data collected in the prospective study.

Grants

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OCTREOTIDE CAPSULES IN PATIENTS WHO PREVIOUSLY TOLERATED AND DEMONSTRATED BIOCHEMICAL CONTROL ON INJECTABLE SOMATOSTATIN RECEPTOR (P&S Industry Clinical Trial)

Nov 3 2017 - Nov 3 2022

ADIPOSE TISSUE AND CIRCULATING MARKERS OF INFLAMMATION IN GH DEFICIENCY AND CHANGES WITH GH THERAPY (P&S Industry Clinical Trial)

Apr 19 2017 - Apr 19 2022

NEW APPROACHES TO THE EVALUATION AND TREATMENT OF ACROMEGALY (Federal Gov)

May 1 2017 - Apr 30 2021

A MULTICENTRE, MULTINATIONAL, RANDOMISED, PARALLEL-GROUP, PLACEBO-CONTROLLED (DOUBLE BLIND) AND ACTIVE-CONTROLLED (OPEN) TRIAL TO COMPARE THE EFFICACY AND SAFETY OF ONCE WEEKLY DOSING OF NNC0195-0092 WITH ONCE WEEKLY DOSING OF PLACEBO AND DAILY (P&S Industry Clinical Trial)

Mar 10 2015 - Mar 10 2020

A PHASE III, MULTI CENTER, DOUBLE BLIND, RANDOMIZED WITHDRAWAL STUDY OF LCI699 FOLLOWING A 24 WEEK, SINGLE ARM, OPEN LABEL DOSE TITRATION AND TREATMENT PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF LCI699 FOR THE TREATMENT OF PATIENTS (P&S Industry Clinical Trial)

Nov 18 2014 - Nov 18 2019

A MULTI-CENTER, RANDOMIZED, OPEN LABEL, PHASE IV STUDY TO INVESTIGATE THE MANAGEMENT OF PASIREOTIDE- INDUCED HYPERGLYCEMIA WITH INCRETIN BASED THERAPY OR INSULIN IN ADULT PATIENTS WITH CUSHING''S DISEASE OR ACROMEGALY (P&S Industry Clinical Trial)

May 9 2014 - May 9 2019

AN ACROMEGALY, OPEN LABEL, MULTI CENTER, SAFETY MONITORING PROGRAM FOR TREATING PATIENTS WITH SOM230 (PASIREOTIDE) LAR WHO HAVE NEED TO RECEIVE MEDICAL THERAPY (ACCESS) (P&S Industry Clinical Trial)

Feb 12 2014 - Feb 12 2019

NEW APPROACHES TO THE EVALUATION AND TREATMENT OF ACROMEGALY (Federal Gov)

Jul 1 2003 - Aug 31 2017

PROSPECTIVE STUDY OF CLINICALLY NON-FUNCTIONING PITUITARY ADENOMAS (Federal Gov)

Mar 1 2010 - Feb 28 2017

PHASE II, OPEN, RANDOMIZED, PARALLEL GROUP, NONCOMPARATIVE MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPEA (P&S Industry Clinical Trial)

Sep 9 2010 - Sep 9 2015

NEW APPROACHES TO THE EVALUATION AND TREATMENT OF ACROMEGALY (Federal Gov)

Sep 30 2010 - Jun 30 2015

BODY COMPOSITION AND THE METABOLIC SYNDROME IN CUSHING S DISEASE (Federal Gov)

Sep 1 2010 - Aug 31 2013

METABOLIC, CARDIOVASCULAR AND BODY COMPOSITION EFFECTS OF SANDOSTATIN LAR THERAPY OF ACROMEGALY EFFECT OF REDUCTION (P&S Industry Clinical Trial)

Sep 28 2006 - Jun 30 2013

ACROSTUDY-POST MARKETING SURVEILLANCE STUDY OF SOMAVERT THERAPY IN PATIENTS WITH ACROMEGALY IN THE US & EUROPE (P&S Industry Clinical Trial)

May 2 2006 - Jun 30 2013

THE GLOBAL HYPOPITUITARY CONTROL AND COMPLICATIONS STUDY (HYPOCCS) (P&S Industry Clinical Trial)

Aug 24 2006 - Feb 28 2013

SOMATULINE DEPOT (LANREOTIDE) INJECTION FOR ACROMEGALY (SODA):A POST-MARKETING OBSERVATIONAL STUDY (P&S Industry Clinical Trial)

Mar 10 2009 - Sep 30 2012

ASSESSMENT OF ENDOTHELIAL FUNCTION IN PATIENTS WITH ACROMEGA LY (Private)

Jul 1 2010 - Jun 30 2012

NOVARTIS -- CSOM230C (P&S Industry Clinical Trial)

Feb 25 2008 - Jun 30 2012

SAFETY AND EFFICACY OF DIFFERENT DOSE LEVELS OF PASIREOTIDE (SOM230)SC OVER A 6 MONTH TREATMENT PERIOD IN PATIENTS WITH (P&S Industry Clinical Trial)

Apr 19 2007 - Oct 31 2011